Genetic heterogeneity profiling for HER2 positive single circulating tumor cell (CTC) in metastatic breast cancer (MBC) by application of DEPArray™ System and single cell DNA sequencing for HER2 positive single circulating tumor cell (CTC) in metastatic breast cancer (MBC) by application DEPArray™ system and single cell DNA sequencing

被引：0
|
作者：
Zhang, Qiang [1 ]
Gerratana, Lorenzo [2 ]
Pivarski, Kara L. [1 ]
Wang, Xinkun [1 ]
Ji, Zhe [1 ]
Stroup, Emily [1 ]
Vagia, Elena Vagia [1 ]
Davis, Andrew Adam Davis A. Adam [1 ]
Shah, Ami [1 ]
Kerby, Katy L. [1 ]
Flaum, Lisa Flaum [1 ]
Wehbe, Firas [1 ]
Zhang, Youbin [1 ]
Qiang, Wenan [1 ]
Behdad, Amir [1 ]
Gradishar, William [1 ]
Platanias, Leonidas [1 ]
Cristofanilli, Massimo [1 ]
机构：
[1] Northwestern Univ Evanston, Chicago, IL USA
[2] Univ Udine, Udine, Italy
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-3120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3120
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts
    Shaw, Jacqueline A.
    Guttery, David S.
    Hills, Allison
    Fernandez-Garcia, Daniel
    Page, Karen
    Rosales, Brenda M.
    Goddard, Kate S.
    Hastings, Robert K.
    Luo, Jinli
    Ogle, Olivia
    Woodley, Laura
    Ali, Simak
    Stebbing, Justin
    Coombes, R. Charles
    CLINICAL CANCER RESEARCH, 2017, 23 (01) : 88 - 96
  • [22] Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA
    Wei, Qing
    Zhang, Yinjie
    Gao, Jing
    Li, Jian
    Li, Jie
    Li, Yanyan
    Zhou, Jun
    Lu, Ming
    Gong, Jifang
    Zhang, Xiaotian
    Shen, Lin
    Sun, Yu
    Chang, Lianpeng
    Wang, Xicheng
    CLINICAL COLORECTAL CANCER, 2019, 18 (03) : 175 - 182
  • [23] HER2 TUMOR HETEROGENEITY AND DISCREPANCIES IN HER2 STATUS BETWEEN PRIMARY TUMOR AND CORRESPONDING CIRCULATING TUMOR CELLS IN METASTATIC BREAST CANCER PATIENTS
    Migliaccio, I.
    Galardi, F.
    Bessi, S.
    Capaccioli, G.
    Biagioni, C.
    Truglia, M.
    Santarpia, L.
    Giannini, A.
    Di Leo, A.
    Pestrin, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 25 - 25
  • [24] Efficacy and safety of pertuzumab for HER2 positive metastatic breast cancer: a single institution experience
    Hara, Fumikata
    Aogi, Kenjiro
    Takashima, Seiki
    ANNALS OF ONCOLOGY, 2015, 26 : 141 - 141
  • [25] Comparison of serum HER2 and CA15-3 in monitoring clinical tumor response in patients with HER2 positive metastatic breast cancer (MBC).
    Kong, SY
    Lee, DH
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 886S - 886S
  • [26] Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer
    Zhang, Qiang
    Qin, Weijun
    D'Amico, Paolo
    Davis, Andrew A.
    Jiao, Jianhua
    Gerratana, Lorenzo
    Jacob, Saya L.
    Zhang, Youbin
    Donahue, Jeannine
    Qiang, Wenan
    Shah, Ami N.
    Behdad, Amir
    Flaum, Lisa
    Gradishar, William
    Platanias, Leonidas C.
    Cristofanilli, Massimo
    CANCER RESEARCH, 2022, 82 (04)
  • [27] Whole Genome Sequencing of Single-Circulating Tumor Cell Ameliorates Unraveling Breast Cancer Heterogeneity
    Li, Yongping
    Jiang, Xiaofei
    Zhong, Ming
    Yu, Bo
    Yuan, Hao
    BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 505 - 513
  • [28] Circulating tumor DNA (ctDNA) mutation (mut) profile in relation to paboclicib (pal) efficacy in hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC)
    Xi, Jing
    Bagegni, Nusayba
    Ademuyiwa, Foluso
    Frith, Ashley
    Suresh, Rama
    Roshal, Anna
    Rigden, Caron
    Hernandez-Aya, Leonel
    Peterson, Lindsay
    Opyrchal, Mateusz
    Clifton, Katherine
    Weilbaecher, Katherine
    Bose, Ron
    Ma, Cynthia
    CANCER RESEARCH, 2021, 81 (04)
  • [29] Single-Cell RNA Sequencing Uncovers Heterogeneous Circulating Tumor Cell Subsets in Breast Cancer
    Papadaki, Maria A.
    Agelaki, Sofia
    CANCERS, 2022, 14 (05)
  • [30] DISEASE FREE INTERVAL (DFI) AND DURATION OF METASTATIC DISEASE (DMD) SEEM TO PREDICT SHIFT OF HER2 STATUS BETWEEN PRIMARY TUMOR AND CIRCULATING TUMOR CELLS (CTC). COMPARISON BETWEEN TWO HER2 NEGATIVE METASTATIC BREAST CANCER (MBC) COHORTS
    Pestrin, M.
    Bessi, S.
    Galardi, F.
    Alessi, B.
    Santoro, A.
    Ravaioli, A.
    Battelli, N.
    Tondini, C.
    Oakman, C.
    Di Leo, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 50 - 50
12345